Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 847
Filtrar
1.
J Public Health Manag Pract ; 30(5): 701-709, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39041765

RESUMEN

The Minnesota Immunization Networking Initiative (MINI) led by Fairview Health Services has addressed barriers to accessing immunizations through partnerships with community organizations to provide free influenza vaccinations to historically underserved communities, especially refugee, immigrant, and migrant communities. Once the COVID-19 vaccine was available, MINI quickly pivoted operations to distribute the vaccine and provide technical assistance to community partners amidst rapidly evolving guidance. With infrastructure and a vaccination team in place, MINI responded to new and emerging needs, eg, implementing a more accessible and low-tech scheduling system, increasing staffing to meet growing needs, and expanding partnerships with community organizations and leaders. From February 2021 to September 2023, MINI organized 1120 community-based vaccine clinics and administered 43,123 COVID-19 vaccinations. Of those vaccine recipients, 88% identified as Black, Indigenous, and other people of color, and for preferred language, over half stated that they preferred a language other than English. These demographics are similar to those of the earlier influenza clinics, even as average annual clinics have tripled and average total vaccinations have quadrupled since the pivot to COVID-19 vaccination clinics. Some keys to success were: (1) consistent, bidirectional communication and shared decision-making with community partners; (2) prioritizing sustainable staffing models with the support of administrative leadership and resources; and (3) having a community-informed approach supported by the practice of hiring staff from communities served. Because of the effectiveness of this model, MINI is primed to respond to planned and unplanned emergent public health crises.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Programas de Inmunización , Gripe Humana , Refugiados , SARS-CoV-2 , Humanos , Minnesota , COVID-19/prevención & control , Refugiados/estadística & datos numéricos , Vacunas contra la COVID-19/provisión & distribución , Vacunas contra la COVID-19/administración & dosificación , Gripe Humana/prevención & control , Programas de Inmunización/métodos , Emigrantes e Inmigrantes/estadística & datos numéricos , Pandemias/prevención & control , Migrantes/estadística & datos numéricos , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/provisión & distribución , Masculino , Femenino , Adulto , Persona de Mediana Edad , Vacunación/estadística & datos numéricos , Vacunación/métodos
4.
Am J Trop Med Hyg ; 105(1): 93-101, 2021 05 10.
Artículo en Inglés | MEDLINE | ID: mdl-33970888

RESUMEN

Each year in Latin America and the Caribbean, seasonal influenza is associated with an estimated 36,500 respiratory deaths and 400,000 hospitalizations. Since the 2009 influenza A(H1N1) pandemic, the Region has made significant advances in the prevention and control of seasonal influenza, including improved surveillance systems, burden estimates, and vaccination of at-risk groups. The Global Influenza Strategy 2019-2030 provides a framework to strengthen these advances. Against the backdrop of this new framework, the University of Colorado convened in October 2020 its Immunization Advisory Group of Experts to review and discuss current surveillance, prevention, and control strategies for seasonal influenza in Latin America and the Caribbean, also in the context of the COVID-19 pandemic. This review identified five areas for action and made recommendations specific to each area. The Region should continue its efforts to strengthen surveillance and impact evaluations. Existing data on disease burden, seasonality patterns, and vaccination effectiveness should be used to inform decision-making at the country level as well as advocacy efforts for programmatic resources. Regional and country strategic plans should be prepared and include specific targets for 2030. Existing investments in influenza prevention and control, including for immunization programs, should be optimized. Finally, regional partnerships, such as the regional networks for syndromic surveillance and vaccine effectiveness evaluation (SARInet and REVELAC-i), should continue to play a critical role in continuous learning and standardization by sharing experiences and best practices among countries.


Asunto(s)
COVID-19/prevención & control , Vacunas contra la Influenza/provisión & distribución , Gripe Humana/prevención & control , COVID-19/complicaciones , Región del Caribe , Salud Global , Humanos , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/complicaciones , América Latina , Estaciones del Año
6.
PLoS One ; 16(4): e0248943, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33831021

RESUMEN

BACKGROUND: Timely knowledge of which influenza vaccine brands are procured and where is of interest to inform site-selection for brand-specific influenza vaccine effectiveness (VE) studies. Vaccine procurement is a key determinant of brand availability. We therefore sought to understand how the procurement for seasonal influenza vaccine in Europe is organized, how this drives brand availability and how procurement data could enable to determine brand availability pre-season. METHODS: Structured telephone interviews were conducted with 15 experts in 16 European countries between 2017 and 2019 to collect information on the influenza vaccine procurement systems. Sources of (brand-specific) procurement data were identified and assessed on public accessibility. Vaccine type and brand availability and timelines were determined for the 2019-20 season to understand how procurement systems drive brand availability and diversity. RESULTS: Four main types of procurement systems for seasonal influenza vaccination campaigns were identified: national public tenders (Croatia, Denmark, Finland, Ireland, Lithuania, Netherlands, Norway, Scotland, Slovenia), regional public tenders (Italy, Spain, Sweden), direct purchase of vaccines by GPs (England, Wales) or pharmacies (Belgium, France, Germany, Greece) from manufacturers or wholesalers. National public tender outcomes are publicly available and timely; brand availability at clinic level can generally be deduced or narrowed down to two brands. Regional tender outcomes are more difficult to find, known very late or not available. In Italian and Spanish regions tenders may be awarded only a few weeks before the seasonal campaign. No public procurement information is available for countries with direct purchase. CONCLUSION: At the country-level, brand diversity is generally lower for countries with national public tenders than for countries with regional public tenders or direct purchase. In only a few countries, procurement data at the brand level is both publicly available and timely. Therefore the usefulness of procurement data for prospective site-selection for brand-specific VE studies is limited.


Asunto(s)
Programas de Inmunización , Vacunas contra la Influenza , Gripe Humana/prevención & control , Europa (Continente) , Humanos , Programas de Inmunización/economía , Programas de Inmunización/provisión & distribución , Vacunas contra la Influenza/economía , Vacunas contra la Influenza/provisión & distribución , Encuestas y Cuestionarios
7.
Multimedia | MULTIMEDIA | ID: multimedia-8396

RESUMEN

O Governador João Doria anunciou nesta quarta-feira (24) a antecipação, para esta sexta-feira (26), do início da vacinação contra COVID-19 para idosos com idade entre 69 e 71 anos. Dados do Plano Estadual de Imunização (PEI) indicam um total de novas 910 mil pessoas aptas a receberem a primeira dose no Estado de São Paulo. “O Governo do Estado de SP antecipou a vacinação das pessoas idosas de 69, 70 e 71 anos para esta sexta-feira, dia 26 de março. A otimização da entrega das vacinas do Butantan e a logística da Secretaria da Saúde estão permitindo a antecipação para o atendimento desta faixa etária. Protejam seus pais, protejam seus avós com a vacina”, disse Doria. A campanha ocorre com uma grande operação logística montada para a distribuição das vacinas disponíveis no país, com envio de remessas semanais pela Secretaria de Estado da Saúde para todas as regiões do Estado. Nesta quarta-feira (24), o Instituto Butantan liberou mais 2,2 milhões de doses de vacina, totalizando a distribuição de 27,8 milhões de doses da vacina contra o coronavírus, desde 17 de janeiro, ao PNI (Programa Nacional de Imunizações) do Ministério da Saúde. Somente em março, o Butantan entregou 14,3 milhões de doses, quantitativo maior do que o disponibilizado em janeiro e fevereiro juntos. O número representa quase 25 mil vacinas por hora. Até o final de abril, o número de vacinas garantidas por São Paulo ao país somará 46 milhões. O Butantan ainda trabalha para entregar outras 54 milhões de doses para vacinação dos brasileiros até 30 de agosto, totalizando 100 milhões de unidades. O pré-cadastro no site “Vacina Já” (vacinaja.sp.gov.br) economiza 90% no tempo de atendimento para imunização: leva cerca de 1 a 3 minutos para quem preencheu o formulário. Presencialmente, em média, a coleta de informações leva cerca de 10 minutos. A ferramenta ajuda a agilizar o atendimento e a evitar aglomerações. Não é um agendamento e o uso não é obrigatório para receber a vacina, mas utilizá-la contribui para melhorar a dinâmica dos serviços e a rotina do próprio cidadão. O pré-cadastro pode ser feito por familiares de idosos ou de qualquer pessoa que participe dos públicos previstos na campanha.


Asunto(s)
Betacoronavirus/inmunología , Infecciones por Coronavirus/prevención & control , Neumonía Viral/prevención & control , Vacunas Virales/provisión & distribución , Pandemias/estadística & datos numéricos , Programas de Inmunización/organización & administración , Sistemas Locales de Salud/organización & administración , Capacidad de Camas en Hospitales/estadística & datos numéricos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Grupos de Riesgo , Monitoreo Epidemiológico , Vacunas contra la Influenza/provisión & distribución
8.
Vaccine ; 39(2): 255-262, 2021 01 08.
Artículo en Inglés | MEDLINE | ID: mdl-33317870

RESUMEN

BACKGROUND: Pandemic planning has historically been oriented to respond to an influenza virus, with vaccination strategy being a key focus. As the current COVID-19 pandemic plays out, the Australian government is closely monitoring progress towards development of SARS-CoV2 vaccines as a definitive intervention. However, as in any pandemic, initial supply will likely be exceeded by demand due to limited manufacturing output. METHODS: We convened community juries in three Australian locations in 2019 to assess public acceptability and perceived legitimacy of influenza pandemic vaccination distribution strategies. Preparatory work included literature reviews on pandemic vaccine allocation strategies and on vaccine allocation ethics, and simulation modelling studies. We assumed vaccine would be provided to predefined priority groups. Jurors were then asked to recommend one of two strategies for distributing remaining early doses of vaccine: directly vaccinate people at higher risk of adverse outcomes from influenza; or indirectly protect the general population by vaccinating primary school students, who are most likely to spread infection. RESULTS: Thirty-four participants of diverse backgrounds and ages were recruited through random digit dialling and topic-blinded social media advertising. Juries heard evidence and arguments supporting different vaccine distribution strategies, and questioned expert presenters. All three community juries supported prioritising school children for influenza vaccination (aiming for indirect protection), one by 10-2 majority and two by consensus. Justifications included that indirect protection benefits more people and is likely to be more publicly acceptable. CONCLUSIONS: In the context of an influenza pandemic, informed citizens were not opposed to prioritising groups at higher risks of adverse outcomes, but if resources and epidemiological conditions allow, achieving population benefits should be a strategic priority. These insights may inform future SARS-CoV-2 vaccination strategies.


Asunto(s)
COVID-19/epidemiología , Asignación de Recursos para la Atención de Salud/organización & administración , Programas de Inmunización/organización & administración , Vacunas contra la Influenza/provisión & distribución , Gripe Humana/prevención & control , Pandemias/prevención & control , Vacunación/ética , Adolescente , Adulto , Australia/epidemiología , Niño , Femenino , Humanos , Esquemas de Inmunización , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/economía , Gripe Humana/epidemiología , Gripe Humana/inmunología , Gripe Humana/virología , Masculino , Persona de Mediana Edad , Orthomyxoviridae/inmunología , Salud Pública/economía , Salud Pública/métodos , SARS-CoV-2/patogenicidad , Vacunación/economía , Cobertura de Vacunación/estadística & datos numéricos
9.
Vaccine ; 39(3): 512-520, 2021 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-33341308

RESUMEN

Vaccines will be an important element in mitigating the impact of an influenza pandemic. While research towards developing universal influenza vaccines is ongoing, the current strategy for vaccine supply in a pandemic relies on seasonal influenza vaccine production to be switched over to pandemic vaccines. Understanding how much vaccine could be produced, in which regions of the world and in what timeframe is critical to informing influenza pandemic preparedness. Through the Global Action Plan for Influenza Vaccines, 2006-2016, WHO promoted an increase in vaccine production capacity and monitors the landscape through periodically surveying influenza vaccine manufacturers. This study compares global capacity for production of influenza vaccines in 2019 with estimates from previous surveys; provides an overview of countries with established production facilities; presents vaccine production by type and manufacturing process; and discusses limitations to these estimates. Results of the current survey show that estimated annual seasonal influenza vaccine production capacity changed little since 2015 increasing from 1.47 billion to 1.48 billion doses with potential maximum annual influenza pandemic vaccine production capacity increasing from 6.37 billion to 8.31 billion doses. However, this figure should be interpreted with caution as it presents a best-case scenario with several assumptions which may impact supply. Further, pandemic vaccines would not be immediately available and could take four to six months for first supplies with several more months needed to reach maximum capacity. A moderate-case scenario is also presented of 4.15 billion doses of pandemic vaccine in 12 months. It is important to note that two doses of pandemic vaccine are likely to be required to elicit an adequate immune response. Continued efforts are needed to ensure the sustainability of this production and to conduct research for vaccines that are faster to produce and more broadly protective taking into account lessons learned from COVID-19 vaccine development.


Asunto(s)
Salud Global , Vacunas contra la Influenza/provisión & distribución , Gripe Humana/prevención & control , Pandemias/prevención & control , Industria Farmacéutica , Humanos , Organización Mundial de la Salud
10.
Vaccine ; 39(3): 495-504, 2021 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-33342632

RESUMEN

The addition of other respiratory illnesses such as flu could cripple the healthcare system during the coronavirus disease 2019 (COVID-19) pandemic. An annual seasonal influenza vaccine is the best way to help protect against flu. Fears of coronavirus have intensified the shortage of influenza shots in developing countries that hope to vaccinate many populations to reduce stress on their health services. We present an inventory-location mixed-integer linear programming model for equitable influenza vaccine distribution in developing countries during the pandemic. The proposed model utilizes an equitable objective function to distribute vaccines to critical healthcare providers and first responders, elderly, pregnant women, and those with underlying health conditions. We present a case study in a developing country to exhibit efficacy and demonstrate the optimization model's applicability.


Asunto(s)
COVID-19/epidemiología , Países en Desarrollo/estadística & datos numéricos , Equipos y Suministros , Vacunas contra la Influenza/provisión & distribución , Salud Pública/métodos , Anciano , Anciano de 80 o más Años , Femenino , Personal de Salud , Humanos , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Embarazo , Vacunación
13.
Multimedia | MULTIMEDIA | ID: multimedia-7165

RESUMEN

A vacinação contra influenza tem o propósito de reduzir complicações, internações e mortes na população alvo para a vacinação no Brasil. Em 2019, acontecerá a 21ª Campanha nacional de vacinação contra a influenza no período de 15 de abril a 31 de maio, sendo 4 de maio, o dia da mobilização nacional.


Asunto(s)
Gripe Humana/prevención & control , Gripe Humana/inmunología , Gripe Humana/epidemiología , Vacunas contra la Influenza/inmunología , Vacunas contra la Influenza/provisión & distribución , Grupos de Riesgo , Vacunación Masiva/organización & administración , Programas de Inmunización/organización & administración , Programas de Inmunización/provisión & distribución
16.
Multimedia | MULTIMEDIA | ID: multimedia-6383

RESUMEN

O Governador João Doria anunciou nesta sexta-feira (28) que as internações por COVID-19 caíram pela quarta semana seguida no estado, pela primeira vez desde o início da pandemia. Entre domingo (23) e quinta-feira (27), foi registrada redução de 9% no número de pacientes internados no estado em comparação com os mesmos dias da semana anterior. São Paulo registrou o menor índice de ocupação de UTI desde o início do Plano São Paulo, com 54,3%. Houve queda também de 9% no número de óbitos entre domingo e quinta-feira em relação ao mesmo período da semana anterior, o que mostra que o estado segue para sua terceira semana seguida de redução de óbitos por COVID-19. Mais informações sobre os dados mais recentes do Plano São Paulo estão disponíveis neste link. “São indicadores que nos trazem otimismo, o pior está passando. Mas isso não deve inibir precaução, zelo, cuidado e atenção no combate à pandemia. Nenhum relaxamento deve ser adotado pelos bons resultados conquistados até aqui”, disse Doria. Em relação à semana epidemiológica anterior, o estado apresentou uma redução de 5% no número de casos, de 10% nas internações e de 11% nos óbitos. Na capital, a queda de casos foi de 2%, 11% de internações e de 6% nos óbitos. Interior e litoral também apresentaram redução: 6% no número de casos, 6% de internações e 18% no índice de óbitos. Nenhuma região foi rebaixada de fase na atualização desta sexta-feira do Plano São Paulo e os 645 municípios paulistas podem permitir a reabertura com restrições do atendimento presencial em comércios e serviços não essenciais. O estado permanece com 88% de sua população em regiões que estão na fase amarela. O Governo do Estado fez um ajuste no Plano São Paulo para aperfeiçoar os indicadores para manutenção na fase verde, evitando que regiões que reduziram sensivelmente os seus números sofram mudanças abruptas de fase, sem que de fato a pandemia tenha se agravado nestes locais. O Plano São Paulo foi concebido com três indicadores para monitoramento da transmissibilidade e da evolução da doença: de novos casos, de óbitos e de internação hospitalar. Estes indicadores foram concebidos para serem analisados de forma comparativa, sempre observando o resultado da semana com os índices da semana anterior. Para dar mais segurança ao plano, o Centro de Contingência do coronavírus implementou dois novos indicadores fixos que determinam que, para passar à fase verde, a região precisa ter no máximo 40 internações por 100 mil habitantes nos últimos 14 dias e 5 óbitos, no máximo, por 100 mil habitantes nos últimos 14 dias. Agora, com este aperfeiçoamento e para preservar a estabilidade das fases, sempre que a região estiver dentro dessa faixa de internações e óbitos, eles serão preponderantes com relação a possíveis alterações nos dados comparativos de internações e óbitos da semana. Caso a região ultrapasse 5 óbitos ou 40 internações por 100 mil habitantes nos últimos 14 dias, a classificação dos indicadores seguirá as regras gerais já vigentes. “Dentre as 22 regiões que são delimitadas pelo Plano SP, 11 destas têm uma taxa inferior a 40 internações por cem mil habitantes, índice este que mede a intensidade da pandemia naquele território”, afirma o Secretário de Desenvolvimento Regional, Marco Vinholi. A partir de agora os vestiários de academias estão liberados para uso dos frequentadores, seguindo os critérios sanitários previstos no Plano São Paulo. A recomendação de autoridades da Saúde é que as pessoas permaneçam em casa se puderem, principalmente idosos e portadores de doenças crônicas. O uso de máscaras em locais de acesso público e no transporte coletivo é obrigatório em todos os 645 municípios.


Asunto(s)
Cuarentena/organización & administración , Monitoreo Epidemiológico , Infecciones por Coronavirus/epidemiología , Neumonía Viral/epidemiología , Betacoronavirus/inmunología , Pandemias/estadística & datos numéricos , Capacidad de Camas en Hospitales/estadística & datos numéricos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Sistemas Locales de Salud/organización & administración , Política Pública , Vacunas contra la Influenza/provisión & distribución , Organización Mundial de la Salud , Institutos Gubernamentales de Investigación , Vacunas Virales/inmunología , Neumonía Viral/inmunología , Infecciones por Coronavirus/inmunología , Vacunas Virales/economía , Financiación de la Atención de la Salud , Agencia Nacional de Vigilancia Sanitaria , Infecciones por Coronavirus/diagnóstico , Neumonía Viral/diagnóstico , Ensayo Clínico Fase III
17.
Hum Vaccin Immunother ; 16(9): 2219-2221, 2020 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-32735161

RESUMEN

In the Northern Hemisphere, the persistence or reemergence of coronavirus circulation into the 2020-2021 influenza season threatens to overwhelm health-care resources and systems and increase mortality and morbidity. Data from Australia show that stay-at-home policies have reduced both influenza and coronavirus cases early in the season, thus "flattening the curve." However, influenza vaccination is critical to ensure the reduction in co-infection. Several policies, such as vaccination strategies to accommodate physical distancing measures, change population recommendations, and timing and location of vaccination have been implemented to increase influenza vaccine uptake during the pandemic. This commentary explores those policies.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Vacunación Masiva , Neumonía Viral/epidemiología , Australia/epidemiología , Betacoronavirus , COVID-19 , Comunicación , Planificación en Salud , Humanos , Vacunas contra la Influenza/provisión & distribución , Gripe Humana/epidemiología , Vacunación Masiva/métodos , Vacunación Masiva/organización & administración , Pandemias , SARS-CoV-2 , Estaciones del Año
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...